ArticleStem cell research & therapy2026
Macrophage autophagy-dependent M2 polarization mediates the protective effect of ADSC-conditioned medium against acute lung injury.
Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAdipose-derived mesenchymal stem cell conditioned medium (ADSC-CM) has emerged as a promising cell-free therapeutic strategy for acute lung injury (ALI). ADSC-CM's anti-inflammatory effect is closely related to its ability to regulate alveolar macrophage polarization. Furthermore, autophagy in macrophages is considered to be related to the regulation of polarization. However, the specific role and mechanisms by which ADSC-CM coordinates autophagy to guide macrophage polarization are not yet fully clear and urgently require further research.
methodsWe established an in vivo rat model of LPS-induced ALI to evaluate the ameliorative effects of ADSC-CM. Concurrently, an in vitro model utilizing NR8383 alveolar macrophages was employed to investigate the underlying mechanisms. A comprehensive suite of techniques, including ELISA, flow cytometry, immunohistochemistry, Western blot, and RT-qPCR, was applied for analysis.
resultIn in vivo experiments, ADSC-CM treatment significantly alleviated LPS-induced pneumonia. In vitro experiments revealed that ADSC-CM enhanced the autophagic flux in NR8383 cells and effectively counteracted the promotion of LPS-driven M1 pro-inflammatory phenotypes, while inducing a shift toward M2 anti-inflammatory phenotypes. This beneficial polarization was proven to be dependent on autophagy, as it was significantly reduced when autophagy was inhibited. Mechanistically, autophagy mediated by ADSC-CM was shown to regulate the STAT1/STAT6 signaling pathway and influence HIF-1α expression.
conclusionOur research results indicate that ADSC-CM alleviates ALI by targeting alveolar macrophages. Its protective mechanism involves enhancing autophagy activity, thereby promoting the polarization of macrophages towards the M2 phenotype through the regulation of STAT1/STAT6 and HIF-1α pathways. This study reveals the immunomodulatory role of ADSC-CM dependent on autophagy, highlighting its potential as an acellular therapeutic strategy for treating ALI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.